PD-L NSCLC
PD-L1Non-Small Cell Lung Cancer (PD-L1+ NSCLC) Market

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer and can be defined as any type of epithelial lung cancer other than SCLC. 

PD-L1 (also known as CD274) is considered an immune checkpoint is facilitating anti-tumour suppression of the immune pathway.


Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Epidemiological Segmentation 

The Epidemiological Segmentation of Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) in 7MM from 2017 to 2030 is segmented as:- 

  • Total Incident Cases of NSCLC
  • Total Incident Cases of NSCLC Patients by Histology
  • Total Diagnosed Cases of NSCLC Patients by Stages
  • Total NSCLC cases of patients by PD-L1
  • Total Treated cases of NSCLC patients by Line of Therapies


Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Epidemiology 

  • Total cases of Programmed death-ligand 1 (PD-L1) mutated NSCLC in 7MM in 2017 were 242,014 Programmed death-ligand 1 (PD-L1) NSCLC cases in the United States in 2017 were 89,597 


Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market

The market size of Programmed death-ligand 1 (PD-L1) mutated NSCLC in 7MM in 2017 was USD 6,536 million. 


Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market Drivers

  • Increasing Use of Biomarker Testing 
  • Increase in the Mutation Specific Trials Activity
  • Increasing Incidence of Programmed death-ligand 1 (PD-L1) mutated NSCLC

 

Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market Barriers

  • Cost-Effectiveness of Therapies
  • Cost of Therapies
  • Burden of Disease


Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Emerging Drugs

The Emerging drugs of the Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) market are 

  • Canakinumab (ACZ885)
  • Avelumab (Bavencio)
  • Libtayo (Cemiplimab)
  • M7824 (Bintrafusp alfa)

And many others. 


Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Key Players

The key players in the Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) market are

  • Novartis Pharmaceutical
  • Merck KGaA 
  • Pfizer
  • Regeneron Pharmaceuticals
  • GlaxoSmithKline

And many others.